Arecor successfully defends a key European Patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage. 

Park occupiers, Arecor Ltd, a leading formulation technology company focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce the successful outcome of the opposition proceedings at the European Patent Office in relation to a key patent of the Company’s broad portfolio that leads to the prevention of aggregation of therapeutic proteins during storage. 

Please click here to view the full release.